Health Alectinib Lands FDA Approval for Adjuvant Therapy in NSCLC Posted on April 20, 2024 by miyuru Oncology/Hematology > Lung Cancer — The ALK inhibitor reduced the risk of recurrence or death by 76% versus chemotherapy by Charles Bankhead, Senior Editor, MedPage Today April 19, 2024 The….
